Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGE AgeX Therapeutics		$4.54	$11.07 ▼ $35.71	$11.99M	1.18	3,849 shs	3,700 shs
EGRX Eagle Pharmaceuticals	$3.70 +0.3%	$2.53	$1.50 ▼ $3.87	$48.05M	0.83	7,688 shs	1,368 shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	45 shs
OSTX OS Therapies	$1.64 -2.4%	$1.72	$1.12 ▼ $7.00	$46.08M	N/A	488,762 shs	348,131 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGE AgeX Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
EGRX Eagle Pharmaceuticals	-1.60%	+3.94%	+57.02%	+105.00%	-38.29%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	+4,900.00%
OSTX OS Therapies	0.00%	+0.60%	-6.15%	+9.80%	+167,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	2.4921 of 5 stars	0.0	3.0	0.0	3.9	0.6	3.3	0.0
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	2.242 of 5 stars	3.7	0.0	0.0	0.0	1.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGE AgeX Therapeutics	0.00	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.40	Buy	$18.00	997.56% Upside

Current Analyst Ratings Breakdown

Latest AGE, OSTX, EGRX, and NBRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGE AgeX Therapeutics	$140K	0.00	N/A	N/A	($16.07) per share	0.00
EGRX Eagle Pharmaceuticals	$257.55M	0.19	$9.25 per share	0.40	N/A	∞
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGE AgeX Therapeutics	-$14.80M	-$13.03	N/A	N/A	N/A	-10,424.65%	N/A	-120.90%	N/A
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGE AgeX Therapeutics	N/A	0.13	0.36
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
NBRV Nabriva Therapeutics	0.12	0.85	0.52
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGE AgeX Therapeutics	12.50%
EGRX Eagle Pharmaceuticals	85.36%
NBRV Nabriva Therapeutics	0.27%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
AGE AgeX Therapeutics	6.50%
EGRX Eagle Pharmaceuticals	28.90%
NBRV Nabriva Therapeutics	1.63%
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGE AgeX Therapeutics	5	1.08 million	1.01 million	Not Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A

AGE, OSTX, EGRX, and NBRV Headlines

Recent News About These Companies

OS Therapies Inc News (OSTX) - Investing.com

4 hours ago | investing.com

OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy

July 14, 2025 | theglobeandmail.com

OS Therapies Raises $4.2M Through Warrant Exercise

July 14, 2025 | tipranks.com

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

July 14, 2025 | newsfilecorp.comN

OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating

July 11, 2025 | tipranks.com

OS Therapies Provides Clinical & Global Regulatory Updates

July 10, 2025 | newsfilecorp.comN

Analysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)

July 3, 2025 | theglobeandmail.com

OSTX - OS Therapies Inc Executives - Morningstar

July 3, 2025 | morningstar.comM

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

July 3, 2025 | businesswire.com

Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress

July 2, 2025 | tipranks.com

OS Therapies' (OSTX) "Buy" Rating Reaffirmed at D. Boral Capital

June 30, 2025 | marketbeat.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...

June 30, 2025 | finance.yahoo.com

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

June 30, 2025 | businesswire.com

OS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2

June 24, 2025 | msn.com

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 24, 2025 | businesswire.com

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

June 23, 2025 | businesswire.com

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 10, 2025 | prnewswire.com

OSTX OS Therapies Incorporated

June 1, 2025 | seekingalpha.com

Buy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer Immunotherapy

May 21, 2025 | tipranks.com

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | businesswire.com

OS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma Treatment

May 16, 2025 | finanzen.atF

New MarketBeat Followers Over Time

Top Headlines

View All

Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
By Thomas Hughes | June 26, 2025
View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks

AGE, OSTX, EGRX, and NBRV Company Descriptions

AgeX Therapeutics NYSE:AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.70 +0.01 (+0.27%)

As of 11:04 AM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

OS Therapies NYSE:OSTX

$1.64 -0.04 (-2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.67 +0.03 (+2.07%)

As of 07:52 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time